In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation

Thrombosis and Haemostasis

Volumn 111, Issue 3, 2013, Pages 474-482

  Gremmel, Thomas ^a   Steiner, Sabine ^a   Seidinger, Daniela ^a   Koppensteiner, Renate ^a   Panzer, Simon ^a   Kopp, Christoph W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angioplasty; Peripheral arterial disease; Platelet reactivity; Stenting

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BODY MASS; EVALUATION AND FOLLOW UP; FEMALE; FLOW CYTOMETER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTICAL DENSITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; PLATELET REACTIVITY; STENTING;

AGED; ANGIOPLASTY; BLOOD PLATELETS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTEGRIN BETA3; MALE; MIDDLE AGED; OLIGOPEPTIDES; P-SELECTIN; PERIPHERAL ARTERIAL DISEASE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, PAR-1; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84893805623     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-07-0558     Document Type: Article

References (24)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001; 345: 494-502.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
3. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
4. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011; 22: 188-195.
5. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
6. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
7. Sibbing D, Morath T, Braun S, et al. Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
8. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to adp detected by a pointof-care assay: A 12-month follow-up. Circulation 2009; 119: 237-242.
9. Siller-Matula JM, Delle-Karth G, Christ G, et al. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2012; 167: 430-435.
10. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
11. Gremmel T, Kopp CW, Seidinger D, et al. Preserved thrombin inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest 2013; 43: 689-697.
12. Gremmel T, Kopp CW, Seidinger D, et al. Impact of diabetes on platelet activation in different manifestations of atherosclerosis. Swiss Med Wkly 2013; 143: 0.
13. Mani H, Kirchmayr K, Klaffling C, et al. Influence of blood collection techniques on platelet function. Platelets 2004; 15: 315-318.
14. Linnemann B, Schwonberg J, Mani H, et al. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: An adjustment for platelet count is not necessary. J Thromb Haemost 2008; 6: 677-683.
15. Siller-Matula JM, Panzer S, Jilma B. Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay. Platelets 2008; 19: 551-554.
16. Gremmel T, Eslam RB, Koppensteiner R, et al. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. Cardiovasc Ther 2013; e40-45.
17. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
18. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011; 106: 211-218.
19. Gremmel T, Steiner S, Seidinger D, et al. The influencing factors for clopidogrelmediated platelet inhibition are assay-dependent. Thromb Res 2011; 128: 352-357.
20. Spiliopoulos S, Pastromas G, Katsanos K, et al. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures-the preclop study: Clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol 2013; 61: 2428-2434.
21. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface p-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
22. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
23. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation 2013; 127: 1522-1529.
24. Welten GM, Schouten O, Hoeks SE, et al. Long-term prognosis of patients with peripheral arterial disease: A comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51: 1588-1596.